By Sabela Ojea

GlaxoSmithKline PLC said Thursday that it has started the Phase 2/3 clinical trials of its plant-derived vaccine candidate against Covid-19, adding that Phase 3 will enroll over 30,000 volunteers world-wide.

The British pharmaceutical giant said the current phase of the trial, being developed in collaboration with Medicago--a biopharmaceutical company--will evaluate the efficacy, immunogenicity, and safety of the vaccine candidate.

"Based on the positive Phase 1 results, Medicago has decided to launch the Phase 2/3 clinical trial with GSK's pandemic adjuvant," GSK said.

Shares at 1309 GMT were up 0.20 pence, or 0.01%, at 1,444.60 pence.

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

(END) Dow Jones Newswires

November 12, 2020 08:34 ET (13:34 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Gsk
Grafico Azioni Gsk (LSE:GSK)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Gsk